Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On September 17, 2021, the FDA announced the approval of Samsung Bioepis and Biogen’s Byooviz (ranibizumab-nuna), a biosimilar to Genentech’s Lucentis (ranibizumab).
Return to publications